Pipeline PipelinePipeline

Spinraza Access and Sites

We will continue to update our community on administration sites, insurance coverage, and community resources and support programs for Spinraza.

Learn MoreLearn More
Conference Conference Conference

2019 Annual SMA Conference

Thanks for a wonderful 2018 Annual SMA Conference! We hope to see you at Disneyland!

Learn MoreLearn More
Events Events Events

Fall Events

Fall event season is in full swing. Join us! Find an upcoming event in your area, or host your own event.

Learn MoreLearn More

AveXis Issues Community Statement on FDA Filing for SMA Type I

AveXis has provided the following community statement on their FDA filing for SMA type I.

Dear SMA Community,

AveXis, a Novartis...

READ MORE

AveXis Files for FDA Approval of Gene Therapy for Spinal Muscular Atrophy <br> Type I

AveXis Files for FDA Approval of Gene Therapy for Spinal Muscular Atrophy
Type I

AveXis, Inc., a Novartis company, today announced that they have filed for FDA approval of AVXS-101, a gene therapy that replaces the survival...

READ MORE

SMA Care Center Network and Clinical Data Registry Launched

SMA Care Center Network and Clinical Data Registry Launched

Cure SMA today announced the launch of our SMA Care Center Network. The SMA Care Center...

READ MORE

Cure SMA Receives Generous Funding from Luke 18:1 Foundation

Cure SMA Receives Generous Funding from Luke 18:1 Foundation

Cure SMA would like to thank the Luke 18:1 Foundation for their generous donations to our

READ MORE

New Spinraza Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with SMA

New Spinraza Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with SMA

Biogen, Inc.

READ MORE

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software